Autopsy report · NCT06231693

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

“The study was stopped due to a realignment of strategic priorities”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 4 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

AstraZeneca

Sponsor type

Industry

Conditions

Breast Cancer

Interventions

Trastuzumab deruxtecan

Participants

2

Sites

2

Countries

Brazil

Trials that died the same way

• Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy
  “study stopped due to company strategic prioritization” (80% match in meaning)
• SHIFT: Studying HIV Immunology After Fecal Transplant
  “The study closed because of shifting research priorities and interests.” (71% match in meaning)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
  “The study was terminated due to strategic business reasons.” (69% match in meaning)
• Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy Routine Care Procedures (GPS Study)
  “Study was cancelled by sponsor due to priority realignment” (68% match in meaning)
• A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
  “Study terminated as part of strategic considerations” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.